Prof. Dr. Ana Martin-Villalba

Prof. Dr. Ana Martin-Villalba

Deutsches Krebsforschungszentrum (DKFZ)
Abteilung Molekulare Neurobiologie
Im Neuenheimer Feld 581
69120 Heidelberg
Phone: +49 (6221) 42-3766
Fax: +49 (6221) 42-3777

Research Area

Stem Cell Biology, Tumor Biology, Axonal De/Regeneration and Neurodegenerative Diseases, CD95 (Fas)

Position and Status

Professor (W3) and Group Leader

Scholarships and awards

2006    Heinz Maier Leibnitz-Preis
2006    Paul Ehrlich und Ludwig Darmstädter Young investigator Award
2006    Walther und Richtzenhain-Preis
1997    Deutscher Akademischer Austauschdienst (DAAD), Bonn

Academic Education

2011   Master of Management, MZSG, St. Gallen, CH
1995   Medical Full Licence to practise (First class honours)


University Degrees

2007   Habilitation (venia legendi), University of Heidelberg
2000   PhD (homologation), Spanish Ministry of Education and Culture, ES
1998   M.D., University of Heidelberg



2011 -   W3 Professor, DKFZ
2011 -   Division Head, Molecular Neurobiology, DKFZ
2006     Group Leader of Molecular Neurobiology, DKFZ
1999     Project Leader in the Dept. Immungenetik, DKFZ


  1. Llorens E, Zhao S, Baser A, Saiz-Castro G, Zwadlo K, Martin-Villalba A (2015) Single celltranscriptomics reveals a population of dormant neural stem cells that become activated upon brain injury. Cell Stem Cell 17:329-340.
  2. Gao L, Brenner D, Llorens-Bobadilla E, Saiz-Castro G, Frank T, Wieghofer P, Hill O, Thiemann M, Karray S, Prinz M, Weishaupt J, Martin-Villalba A (2015) Infiltration of circulating myeloid cells through CD95l contributes to neurodegeneration in mice. J. Exp. Med. 212:469-480.
  3. Ziebell F, Martin-Villalba A, Marciniak-Czochra A. (2014) Mathematical modelling of adult hippocampal neurogenesis: effects of altered stem cell dynamics on cell counts and bromodeoxyuridine-labelled cells. J. R. Soc. Interface 11:20140144.
  4. Seib DRM, Corsini NS, Ellwanger K, Plass C, Mateos A, Pitzer C, Niehrs C, Celikel T, MartinVillalba A. (2013) Loss of Dickkopf-1 restores neurogenesis in old age and counteracts cognitive decline. Cell Stem Cell 12:204-214.
  5. Letellier E., Kumar S, Sancho-Martinez I, Krauth S, Funke-Kaiser A, Laudenklos S, Konecki K, Klussmann S, Corsini NS, Kleber S, Drost N, Neumann A, Levi-Strauss M, Brors B, Gretz N, Edler L, Fischer C, Hill O, Thiemann M, Biglari B, Karray S, Martin-Villalba A. (2010). CD95-ligand on peripheral myeloid cells activates Syk kinase to trigger their recruitment to the inflammatory site. Immunity 32:240-252.
  6. Corsini N, Sancho-Martinez I, Laudenklos S, Glagow D, Kumar S, Letellier E, Koch P, Teodorczyk M, Kleber S, Klussmann S, Wiestler B, Brüstle O, Gieffers C, Hill O, Thiemann M, Seedorf M, Gretz N, Sprengel R, Celikel T, Martin-Villalba A. (2009) The death receptor CD95 activates adult neural stem cells for working memory formation and brain repair. Cell Stem Cell 5:178-190.
  7. Kleber S, Sancho-Martinez I, Wiestler B, Beisel A, Gieffers C, Hill O, Thiemann M, Mueller W, Sykora J, Kuhn A, Schreglmann N, Letellier E, Zuliani C, Klussmann S, Teodorczyk M, Grone HJ, Ganten TM, Sultmann H, Tuttenberg J, von Deimlling A, Regnier-Vigouroux A, Herold-Mende C, Martin-Villalba A (2008) Yeas and PI3K bind CD95 to signal invasion of glioblastoma. Cancer Cell 13: 235-248.
  8. Demjen D, Klussmann S, Kleber S, Zuliani C, Stieltjes B, Metzger C, Hirt UA, Walczak H, Falk W, Essig M, Edler L, Krammer PH, Martin-Villalba A. (2004) Neutralization of CD95 ligand promotes regeneration and functional recovery after spinal cord injury. Nat. Med. 10:389-395.

Review articles

  1. Martin-Villalba A, Llorens-Bobadilla E, Wollny D. (2013). CD95 in cancer: tool or target? Trends Mol. Med. 19:329-335.
  2. Sancho-Martinez I, Martin-Villalba A. (2009). Tyrosine phosphorylation and CD95: a FAScinating switch. Cell Cycle 15: 838-42.


  • Applied for:
    • “Use of CD95 inhibitors for the treatment of inflammatory disorders”; PCT/EP2009/00 “Compounds inhibiting CD95 signaling for the treatment of pancreatic cancer”; EP (16.11.2009) 09 176 099.1
  • Granted:
    • “Combination of therapies to inhibit CD95L and TNF” EP 1 235 592 granted November 14, 2007 in Europe (Deutschland, Schweiz) AU 784102 granted May 18, 2006 in Australia OC&locale=en_EP&CC=EP&FT=D
    • “Inhibition of the CD95 ligand/receptor system for the treatment of CNS trauma” EP 1 592 446 granted May 7, 2008 in Europe (nationalisiert in: Frankreich, Belgien, Irland, Deutschland, Spanien, UK, Italien, Niederlande, Österreich, Schweden, Schweiz, Dänemark) OC&locale=en_EP&CC=EP&FT=D ; exclusively licenced to Apogenix GmbH
    • “Neutralization of CD95 Activity Blocks Invasion of Glioblastoma Cells in Vivo”; PCT (WO2008080623); 080623A2&DB=EPODOC&locale=en_EP&CC=WO&FT=D
    • “The death receptor CD95 controls neurogenesis of adult neural stem cell in vivo and in vitro”; PCT (WO2008034608); 034608A1&DB=EPODOC&locale=en_EP&CC=WO&FT=D